The primary research question for which these data have been used, was: ‘How patient-relevant are outcomes measured in clinical trials for breast cancer drugs?’. Subquestions were: 1. Which treatment outcomes are relevant for breast cancer patients? 2. Which outcome measures are used in clinical trials for breast cancer drugs? 3. How much overlap is there between patient-relevant outcomes and outcomes measured in clinical trials?The dataset has been used to answer subquestion 2. Data have been obtained by searching Clinicaltrials.gov for trials conducted between January 2014 and March 2024 inclusive. Further inclusion criteria were that studies had to be phase III trials and had to focus on breast cancer, adults (18-64 years old) and drugs. Interventions focusing on lifestyle changes, Chinese medicine, anaesthesia, surgery and diagnostic methods were excluded. Ultimately, 264 trials were included and forty-five excluded. To determine the outcome measures used, the study plan of every included trial was reviewed and recorded on the data sheet.

This entry is a three-file data package totaling 3.2 MB, containing files in .pdf, .txt and .ods formats.If you use this dataset, please cite: Delnoij, Diana; Plooij, Jasmijn (2025). Patient-relevance of outcome measures in breast cancer clinical trials - Data Files. Erasmus University Rotterdam (EUR). Dataset. https://doi.org/10.25397/eur.28314236